{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:24:14Z","timestamp":1789514654304,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cld.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:30:49Z","timestamp":1747899049000},"page":"469-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Liver in Hematologic Malignancies"],"prefix":"10.1016","volume":"29","author":[{"given":"Natalia","family":"Zbib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gambarin-Gelwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cld.2025.03.009_bib1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(10)70167-4","article-title":"Hepatitis B virus infection and risk of Non-Hodgkin lymphoma in South Korea: a cohort study","volume":"11","author":"Engels","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.cld.2025.03.009_bib2","first-page":"554","article-title":"High prevalence of hepatitis B virus infection in B-cell non-hodgkin\u2019s lymphoma","volume":"91","author":"Marcucci","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cld.2025.03.009_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.695384","article-title":"Hepadnaviral lymphotropism and its relevance to HBV persistence and pathogenesis","volume":"12","author":"Coffin","year":"2021","journal-title":"Front Microbiol"},{"issue":"15","key":"10.1016\/j.cld.2025.03.009_bib4","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.7150\/jca.31033","article-title":"Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review","volume":"10","author":"Rong","year":"2019","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.cld.2025.03.009_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejh.13300","article-title":"Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma","volume":"103","author":"Zhou","year":"2019","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.03.009_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.03.009_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"issue":"31","key":"10.1016\/j.cld.2025.03.009_bib10","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cld.2025.03.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01393","article-title":"Late hepatitis B reactivation after treatment with rituximab","volume":"27","author":"Pereira","year":"2022","journal-title":"IDCases"},{"issue":"10","key":"10.1016\/j.cld.2025.03.009_bib12","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cld.2025.03.009_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/jvh.12713","article-title":"The impact of hepatitis B virus infection and vaccination on the development of Non-Hodgkin lymphoma","volume":"24","author":"Huang","year":"2017","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib14","first-page":"183","article-title":"The pathogenesis of hepatitis C virus-associated B-cell Non-Hodgkin lymphoma","volume":"10","author":"Giannelli","year":"2003","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.009_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"9956","key":"10.1016\/j.cld.2025.03.009_bib16","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cld.2025.03.009_bib17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.cld.2025.03.009_bib18","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.22.00668","article-title":"Direct-acting antivirals as primary treatment for hepatitis C virus-associated indolent non-hodgkin lymphomas: the BArT study of the Fondazione Italiana linfomi","volume":"40","author":"Merli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.009_bib19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"Abramson NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.cld.2025.03.009_bib20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series\u2606","volume":"73","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2025.03.009_bib22","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1634\/theoncologist.2018-0331","article-title":"Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas","volume":"24","author":"Merli","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jmv.23754","article-title":"Risk of hepatocellular carcinoma and cancers at other sites among patients diagnosed with chronic hepatitis B virus infection in Sweden","volume":"86","author":"Sundquist","year":"2014","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1186\/s12885-016-2918-5","article-title":"Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan","volume":"16","author":"Kamiza","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.cld.2025.03.009_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5718","article-title":"Associations between hepatitis B virus infection and risk of all cancer types","volume":"2","author":"Song","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1155\/2014\/780350","article-title":"Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemia","volume":"28","author":"Minuk","year":"2014","journal-title":"Canadian J Gastroenterol hepatol"},{"key":"10.1016\/j.cld.2025.03.009_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.2830460405","article-title":"Hepatitis C virus infection in patients with leukemia","volume":"46","author":"Fujii","year":"1994","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.cld.2025.03.009_bib28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cld.2025.03.009_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.03.009_bib30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","article-title":"Hepatitis C virus infection in patients with cancer: impact on clinical trial enrolment , selection of therapy, and prognosis","volume":"157","author":"Torres","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2025.03.009_bib31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.leukres.2015.09.008","article-title":"Hepatitis B seropositivity and risk of developing multiple myeloma or hodgkin lymphoma: a meta-analysis of observational studies","volume":"39","author":"Dalia","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/imj.12981","article-title":"Association between hepatitis B virus infection and risk of multiple myeloma: a systematic review and meta-analysis","volume":"46","author":"Li","year":"2016","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib33","first-page":"272","article-title":"Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses","volume":"109","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cld.2025.03.009_bib34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jvh.12742","article-title":"Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies","volume":"24","author":"Li","year":"2017","journal-title":"J Viral Hepat"},{"issue":"12","key":"10.1016\/j.cld.2025.03.009_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(08)70307-3","article-title":"Part II: liver function in oncology: towards safer chemotherapy use","volume":"9","author":"Field","year":"2008","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.009_bib36","doi-asserted-by":"crossref","first-page":"e981","DOI":"10.1016\/j.clml.2022.07.006","article-title":"Clinical characteristics and management of patients with concomitant liver cirrhosis and lymphoma: a systematic review","volume":"22","author":"Jelicic","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.cld.2025.03.009_bib37","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2169\/internalmedicine.0092-17","article-title":"Patient with non-alcoholic steatohepatitis complicated by multiple myeloma","volume":"57","author":"Akashi","year":"2018","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.23998","article-title":"Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis","volume":"53","author":"Syn","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.cld.2025.03.009_bib39","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.cld.2025.03.009_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-018-3565-5","article-title":"Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence?","volume":"98","author":"Haefliger","year":"2019","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.009_bib41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.dld.2020.04.024","article-title":"A long-term follow-up of primary hepatic mucosa-associated lymphoid tissue lymphoma","volume":"52","author":"Chen","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib42","first-page":"250","article-title":"Primary hepatic marginal zone lymphoma in a patient with chronic hepatitis C","volume":"11","author":"Gherlan","year":"2016","journal-title":"Maedica"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib43","article-title":"Primary hepatic lymphoma mimicking a hepatocellular carcinoma in a cirrhotic patient: case report and systematic review of the literature","author":"Bohlok","year":"2018","journal-title":"Case reports in surgery"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4254\/wjh.v9.i3.155","article-title":"Primary mucosa-associated lymphoid tissue lymphoma of the liver: a report of two cases and review of the literature","volume":"9","author":"Obiorah","year":"2017","journal-title":"World J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.0902-4441.2003.00203.x","article-title":"Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia","volume":"72","author":"Yoshida","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cld.2025.03.009_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bbmt.2009.01.013","article-title":"The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms","volume":"15","author":"Palomo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cld.2025.03.009_bib47","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cld.2025.03.009_bib48","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.cld.2025.03.009_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cld.2025.03.009_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.cld.2025.03.009_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","article-title":"Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation","volume":"40","author":"Cheuk","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.cld.2025.03.009_bib52","first-page":"3599","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cld.2025.03.009_bib53","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12185-014-1578-y","article-title":"Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant","volume":"99","author":"Maximova","year":"2014","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.cld.2025.03.009_bib54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2000.18.5.981","article-title":"Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies","volume":"18","author":"Girinsky","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cld.2025.03.009_bib55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bbmt.2019.01.019","article-title":"SessaLiver stiffness measurement allows early diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: results from a monocentric prospective study","volume":"25","author":"Colecchia","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cld.2025.03.009_bib56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cld.2025.03.009_bib57","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","article-title":"The use of defibrotide in blood and marrow transplantation","volume":"2","author":"Richardson","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cld.2025.03.009_bib58","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cld.2025.03.009_bib59","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cld.2025.03.009_bib60","first-page":"443","article-title":"Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS)","volume":"18","author":"L\u00e9vy","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.cld.2025.03.009_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bmt.1702386","article-title":"Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation","volume":"25","author":"Azoulay","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.cld.2025.03.009_bib62","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.03.009_bib63","first-page":"S21","article-title":"Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD)","volume":"7","author":"Matsukuma","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.009_bib64","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612500025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612500025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:29:42Z","timestamp":1752676182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612500025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S108932612500025X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.03.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Liver in Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}